IPSEN (OTCMKTS:IPSEY) Sees Strong Trading Volume – What’s Next?

Shares of IPSEN (OTCMKTS:IPSEY) saw unusually-strong trading volume on Tuesday . Approximately 4,364 shares traded hands during mid-day trading, an increase of 37% from the previous session’s volume of 3,177 shares.The stock last traded at $46.31 and had previously closed at $46.1450.

Analyst Ratings Changes

A number of research firms have weighed in on IPSEY. UBS Group cut shares of IPSEN from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 8th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a research report on Tuesday, February 17th. Finally, BNP Paribas Exane downgraded IPSEN to an “underperform” rating in a research report on Wednesday, November 26th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold”.

IPSEN Price Performance

The stock has a fifty day moving average of $40.68 and a two-hundred day moving average of $36.89.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).